Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 | +$574M | |
| 2 | +$573M | |
| 3 | +$446M | |
| 4 |
Micron Technology
MU
|
+$389M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$387M |
Top Sells
| 1 | +$1.19B | |
| 2 | +$1.11B | |
| 3 | +$557M | |
| 4 |
Autodesk
ADSK
|
+$554M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$490M |
Sector Composition
| 1 | Technology | 34.83% |
| 2 | Healthcare | 19.29% |
| 3 | Consumer Discretionary | 9.89% |
| 4 | Financials | 9.74% |
| 5 | Industrials | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
The Bancorp
TBBK
$2.25B
| $61.6M | 0.03% |
912,067
-262,192
|
|
||
377
Kirby Corp
KEX
$6.79B
| $61.5M | 0.03% |
558,300
-27,074
|
|
||
378
Intel
INTC
$234B
| $61.5M | 0.03% |
1,666,719
+7,729
|
|
||
379
Arcellx
ACLX
$6.69B
| $60M | 0.03% |
919,578
-94,343
|
|
||
380
Spyre Therapeutics
SYRE
$3.26B
| $59.9M | 0.03% |
1,829,009
+1,816,009
|
|
||
381
Vanguard FTSE Emerging Markets ETF
VWO
$113B
| $59.1M | 0.03% |
1,100,122
-14,159
|
|
||
382
Janus Henderson AAA CLO ETF
JAAA
$27.1B
| $59M | 0.03% |
1,166,319
-573,210
|
|
||
383
Enanta Pharmaceuticals
ENTA
$405M
| $58.8M | 0.03% |
3,729,659
+1,782,745
|
|
||
384
Halozyme
HALO
$8B
| $58.1M | 0.03% |
863,956
-94,073
|
|
||
385
Medpace
MEDP
$13.2B
| $58M | 0.03% |
103,245
+9,961
|
|
||
386
Travelers Companies
TRV
$65.4B
| $58M | 0.03% |
199,805
-3,820
|
|
||
387
BioCryst Pharmaceuticals
BCRX
$2.19B
| $57.8M | 0.03% |
7,404,386
+7,310,745
|
|
||
388
Exxon Mobil
XOM
$617B
| $57.5M | 0.03% |
478,018
+72,085
|
|
||
389
American Homes 4 Rent
AMH
$10.7B
| $56.2M | 0.03% |
1,749,424
-47,767
|
|
||
390
Littelfuse
LFUS
$8.13B
| $55.4M | 0.02% |
219,039
-1,845
|
|
||
391
Ceco Environmental
CECO
$1.94B
| $55.2M | 0.02% |
922,000
+1,898
|
|
||
392
Lexeo Therapeutics
LXEO
$526M
| $54.7M | 0.02% |
5,509,635
-595,892
|
|
||
|
EXE
393
Expand Energy Corp
EXE
$25.2B
| $54.4M | 0.02% |
492,758
+20,066
|
|
||
394
Alnylam Pharmaceuticals
ALNY
$42.8B
| $54.3M | 0.02% |
136,425
+570
|
|
||
395
Franklin FTSE United Kingdom ETF
FLGB
$972M
| $54.2M | 0.02% |
1,606,862
-17,759
|
|
||
396
Krystal Biotech
KRYS
$7.63B
| $54.1M | 0.02% |
219,440
+209,369
|
|
||
397
Advanced Micro Devices
AMD
$331B
| $54M | 0.02% |
252,552
+1,622
|
|
||
398
Amylyx Pharmaceuticals
AMLX
$1.65B
| $54M | 0.02% |
4,465,872
+1,929,639
|
|
||
399
EyePoint Inc
EYPT
$1.28B
| $53.7M | 0.02% |
+2,937,729
|
|
||
400
Crane Co
CR
$11B
| $53.5M | 0.02% |
290,184
+52,419
|
|